Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights
and shares composing the share capital
(in accordance with Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)
Market: Euronext Paris
ISIN Code: FR 0010259150
LEI: 549300M6SGDPB4Z94P11
| Date | Total number of shares composing the share capital | Total number of voting rights (1) |
| 30 June 2024 | 83,814,526 | Gross total* of voting rights: 132,146,651 |
| Net total** of voting rights: 131,218,212 |
(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).
* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.
** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.
Attachment
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis